ESMO Media Releases

A novel treatment strategy with personalised cell therapy significantly improves progression-free survival compared to standard immunotherapy in patients with advanced melanoma

Significant improvement in progression free survival and response rate combined with reduced symptoms and better quality of life are reported as outcomes of a new treatment approach for patients with desmoid tumours

A new mechanism has been identified through which very small pollutant particles in the air may trigger lung cancer in people who have never smoked, paving the way to new prevention approaches and development of therapies

Sustainability will be at the heart of many discussions at the ESMO Congress 2022 , as illustrated by the new results and initiatives spanning cancer prevention, early detection and treatment that were announced today during the opening press conference

ESMO and EONS announce the launch of the ground-breaking, Europe-wide “Cancer Prevention Across Europe” campaign (PrEvCan) aimed at reducing the burden of cancer

The ESMO Congress 2022 will be held in person in Paris and virtually between 9-13 September 2022.

The ESMO World Congress on Gastrointestinal Cancer, the annual event dedicated to the presentation and discussion of new findings in GI cancer treatment, research and care, will be held as a fully onsite event in Barcelona, Spain, from 29 June to 2 July 2022.

Data from two large cancer centres in the United States have shown that the COVID-19 pandemic caused substantial disruption to clinical trials for cancer treatment and care.

The ESMO Gynaecological Cancers Congress 2022, the annual event dedicated to improving the practice of gynaecological cancers specialists worldwide, will provide insights into the latest treatments, biology and biomarkers of ovarian, uterine, cervical and rare cancers.

The evidence-based tool is designed to help interpret data from a heterogeneous research landscape

The ESMO Breast Cancer Congress 2022, the annual event dedicated to advancing the science, disseminating education and improving the practice of breast cancer specialists worldwide, will focus this year on integrating translational research for innovative clinical practice.

A consensus reached by a lung clinical community within the International Cancer Benchmarking Partnership (ICBP), presented at the ELCC, 30 March – 2 April 2022, has highlighted international disparities in management and outcomes of patients with lung cancer in high-income countries, and has provided a roadmap of key actions that should be taken to homogenise practices, help enable earlier diagnosis and offer equitable access to care.